Why Aptose Biosciences Plunged 45% Yesterday

Aptose Biosciences (TSX:APT)(NASDAQ:APTO) results for its leukemia drug were met with a poor reaction, sending shares down 45%.

| More on:

Aptose Biosciences (TSX:APT)(NASDAQ:APTO) shares crashed 45% on Tuesday after results from its leukemia trial were met with a less-than-ideal reaction.

What happened?

The biotechnology company focused on oncology reported its oral, once-daily myeloid kinome inhibitor (MKI) phase-one-of-two study. The company believes it showed “meaningful benefit in all responders” in the 34-patient study. It’s a difficult area of study, as acute myelogenous leukemia (ACL) relapses are incredibly difficult to treat.

Its current trial, named luxeptinib, aims at creating a “next generation” formula, to “reduce pill burden, improve absorption, and increase exposure.” The new formula aims to begin testing by the first half of 2022.

The news became public on Monday evening, sending shares in a downward spiral almost immediately. Shares reached a trough price, down 45% on Tuesday. Shares currently trade at $1.44 as of writing.

So what?

This new study continues the bad share news for Aptose, despite analysts continuing to recommend it as a strong buy. It seems that investors don’t want to wait for action and remain unconvinced for a while now. The last report back in June was also met with lukewarm results.

The problem is that it’s been far too much waiting for investors regarding Aptose. Everyone wants the next big thing after the COVID-19 vaccine. A treatment for cancer would certainly be a great place to look. However, Aptose continues to see more trials and small results.

Now what?

Analysts are of mixed minds when it comes to Aptose. On the one hand, it could be a good momentum buy if you’re watching it like a hawk. On the other hand, it’s not valuable at the moment. Its fundamentals are weak, with a -1.93 EV/EBITDA and price-to-book ratio of two. Further, it continues to operate at a loss, with its most recent earnings coming in at a loss of $55 million. And that loss has grown larger and larger as the quarters continue on.

If Aptose can’t convince investors that its next drug is worth the wait soon, it may be out of long-term luck. So, I wouldn’t look at this week’s collapse in share price as an opportunity. I’d definitely wait and see what happened in 2022 before buying even a share of Aptose.

Shares of Aptose are down 75% year to date.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Amy Legate-Wolfe has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned.

More on Investing

The virtual button with the letters AI in a circle hovering above a keyboard, about to be clicked by a cursor.
Tech Stocks

Emerging Canadian AI Companies With Big Potential

These tech stocks are paving the way to an AI-filled future, but still offer enough growth ahead for a strong…

Read more »

Young Boy with Jet Pack Dreams of Flying
Tech Stocks

Is Constellation Software Stock a Buy, Sell, or Hold for 2025?

CSU stock has long been a strong option for high growth, high value stocks. But are there now too many…

Read more »

rising arrow with flames
Investing

2 Riskier Stocks With High Potential for Canadian Investors in November

Risky stocks such as Well Health Technologies have the potential to provide life-changing long-term returns.

Read more »

hand stacks coins
Dividend Stocks

3 Ultra-High-Yield Dividend Stocks You Can Buy and Hold for a Decade

These three high-yield dividend stocks still have some work to do, but each are in steady areas that are only…

Read more »

senior man and woman stretch their legs on yoga mats outside
Dividend Stocks

TFSA: 2 Canadian Stocks to Buy and Hold Forever

Here are 2 TFSA-worthy Canadian stocks. Which one is a good buy for your TFSA today?

Read more »

Canada day banner background design of flag
Investing

Got $500? 5 Top Canadian Stocks to Buy and Hold

These top Canadian stocks have solid fundamentals with potential to outperform the benchmark index by a wide margin.

Read more »

man touches brain to show a good idea
Energy Stocks

1 No-Brainer Energy Stock to Buy With $500 Right Now

Should you buy a cyclical energy stock at its decade-high? Probably not. But read this before you make a decision.

Read more »

Asset Management
Stocks for Beginners

TFSA: 4 Canadian Stocks to Buy and Hold Forever

Thinking about what to buy with the new TFSA contribution space in 2025? These four Canadian stocks are worth holding…

Read more »